sur Pharnext (EPA:ALPHA)
Pharnext begins liquidation proceedings
Paris, August 27, 2024 – Pharnext SCA, a biopharmaceutical company specializing in neurodegenerative diseases, announced the opening of its compulsory liquidation by the Paris Commercial Court on August 22.
Pharnext had previously informed that it could no longer finance its activity beyond the conciliation procedure closed on July 15, 2024. The company had therefore requested this liquidation itself, a request accepted by the court.
SELAFA MJA, represented by Maître Lucile Jouve, will be responsible for the liquidation. The listing of Pharnext shares is suspended as of August 27, 2024.
Creditors have priority over Pharnext's assets; shareholders should therefore not receive any payment when the assets are sold.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pharnext